

USSN:10/776,934

Group Art Unit:1635

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims

1. (Canceled)
2. (Canceled)
3. (Currently Amended) The compound according to claim ~~1~~53 consisting of from ~~[[8]]~~12-40 nucleotides.
4. (Canceled)
5. (Currently Amended) The compound according to claim ~~[[4]]~~3 consisting of from 12-20 nucleotides.
6. (Original) The compound according to claim 5 consisting of 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides.
7. (Original) The compound according to claim 6 consisting of 14, 15, 16, 17 or 18 nucleotides.
8. (Original) The compound according to claim 5 consisting of from 15-17 nucleotides.
9. (Original) The compound according to claim 8 consisting of 15, 16 or 17 nucleotides.
10. (Original) The compound according to claim 8 consisting of 15 nucleotides.
11. (Original) The compound according to claim 9 consisting of 16 nucleotides.

USSN:10/776,934

Group Art Unit:1635

12. (Original) The compound according to claim 9 consisting of 17 nucleotides.
13. (Currently Amended) The compound according claim ~~[[1]]153~~, comprising a subsequence of at least 10 nucleotides or nucleotide analogues.
14. (Currently Amended) The compound according to claim ~~[[1]]153~~, comprising a subsequence of at least 12 nucleotides or nucleotide analogues.
15. (Currently Amended) The compound according to claim ~~[[1]]153~~, comprising a subsequence of at least 14 nucleotides or nucleotide analogues.
16. (Currently Amended) The compound according to claim ~~[[1]]153~~, comprising a subsequence of 10, 11, 12, 13 14, 15 or 16 nucleotides or nucleotide analogues.
17. (Cancel)
18. (Cancel)
19. (Currently Amended) The compound according to claim ~~18~~160, wherein said linkage is a phosphate group.
20. (Currently Amended) The compound according to claim ~~17~~ 160, wherein said linkage is phosphorothioate group.
21. (Currently Amended) The compound according to claim ~~20~~ 160, wherein all nucleotides comprise a phosphorothioate group.
22. (Cancel).

USSH:10/776,934

Group Art Unit:1635

23. (Currently Amended) The compound according to claim ~~22~~ 153 comprising of from 1-50 nucleotide analogues.
24. (Original) The compound according to claim 23 comprising of from 2-45 nucleotide analogues.
25. (Original) The compound according to claim 24 comprising of from 3-40 nucleotide analogues.
26. (Original) The compound according to claim 25 comprising of from 4-35 nucleotide analogues.
27. (Original) The compound according to claim 26 comprising of from 5-30 nucleotide analogues.
28. (Original) The compound according to claim 27 comprising of from 6-25 nucleotide analogues.
29. (Original) The compound according to claim 28 comprising of from 6-20 nucleotide analogues.
30. (Original) The compound according to claim 29 comprising of from 6-12 nucleotide analogues.
31. (Original) The compound according to claim 30 comprising of from 8-12 nucleotide analogues.
32. (Original) The compound according to claim 30 comprising 6, 7, 8, 9, 10, 11 or 12 nucleotide analogues.

USSH:10/776,934

Group Art Unit:1635

33. (Original) The compound according to claim 31 comprising of from 6-10 nucleotide analogues.

34. (Original) The compound according to claim 33 comprising 6, 7, 8, 9 or 10 nucleotide analogues.

35. (Original) The compound according to claim 34 comprising 7, 8 or 9 nucleotide analogues.

36. (Original) The compound according to claim 35 comprising 8 nucleotide analogues.

37. (Currently Amended) The compound according to any of claims ~~2223~~-36, wherein all nucleotides are replaced by the corresponding nucleotide analogues.

38. (Currently Amended) The compound according to any of claims ~~2223~~-36 comprising a nucleoside located at the 3' end.

39.-44 (Cancel)

45. (Currently Amended) The compound according to claim ~~[[44]] 153~~, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphate group.

46. (Currently Amended) The compound according to claim ~~[[44]] 153~~, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphorothioate group.

47. (Cancel)

USSN:10/776,934

Group Art Unit:1635

48. (Currently Amended) The compound according to ~~any of claims 44-47~~ claim 153, wherein said subsequence comprises a stretch of 2-6 LNAs ~~as defined in any of claims 39-43~~ followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-6 LNAs ~~as defined in any of claims 39-43~~.

49. (Currently Amended) The compound according to claim 48, wherein said subsequence comprises a stretch of 4 LNAs ~~as defined in any of claims 39-43~~ followed by a stretch of 8 nucleotides, which is followed by a stretch of 4 LNAs ~~as defined in any of claims 39-43~~.

50. (Currently Amended) The compound according to claim ~~47~~ 153, wherein said subsequence comprises a stretch of 2-6 LNAs ~~as defined in any of claims 39-43~~ followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-5 LNAs ~~as defined in any of claims 39-43~~, which is followed by a single nucleotide.

51. (Currently Amended) The compound according to claim 50, wherein said subsequence comprises a stretch of 4 LNAs ~~as defined in any of claims 39-43~~ followed by a stretch of 8 nucleotides, which is followed by a stretch of 3 LNAs ~~as defined in any of claims 39-43~~, which is followed by a single nucleotide.

52. (Previously Presented) The compound according to claim 51, wherein said single nucleoside is located at the 3' end.

53. - 119 (Cancel)

120. (Currently Amended) A conjugate comprising the compound according to claim ~~[[1]]~~ 153 and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said compound.

USPN:10/776,934

Group Art Unit:1635

121. (Currently Amended) A pharmaceutical composition comprising a compound as defined in claim [[1]] 153 or a conjugate as defined in claim 120, and a pharmaceutically acceptable diluent, carrier or adjuvant.

122. (Previously Presented) The pharmaceutical composition according to claim 121 further comprising at least one chemotherapeutic agent.

123. (Previously Presented) The pharmaceutical composition according to claim 122, wherein said chemotherapeutic compound is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; alretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriamycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (flouxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idarubicin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorethamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamycin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); procarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

USSN:10/776,934

Group Art Unit:1635

124. (Currently Amended) A compound as defined in claim ~~[[1]] 153~~ or a conjugate as defined in claim 120 for use as a medicament.

125-152 (Cancel)

153. (New) A compound consisting of 12-50 nucleotides and/or nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within the sequence ctcaatccatggcagc and wherein at least one of said nucleotides in said sequence has been replaced by a corresponding nucleotide analogue.

154. (New) The compound of claim 153, wherein said corresponding nucleotide is selected from the group consisting of LNA sugar, 2'-O-methyl DNA sugar, 2'-fluoro DNA sugar, 2'-MOE DNA sugar, 2'-O-(3-amino)propyl and 2'-O-(3-hydroxy)propyl.

155. (New) The compound of claim 154, wherein said corresponding nucleotide is LNA.

156. (New) The compound of claim 155, wherein said LNA is selected from the group consisting of thio-LNA, amino-LNA and oxy-LNA.

157. (New) The compound of claim 156, wherein said LNA is beta-D-oxy-LNA.

158. (New) The compound of claim 153, wherein said compound comprises a subsequence of at least 12 nucleotides or nucleotide analogues.

159. (New) The compound of claim 153, wherein said compound consists of 12-20 nucleotides and/or nucleotide analogues.

160. (New) The compound of claim 153, wherein said compound comprises the sequence CTCAatccatggCAGC or CTCAatccatggCAGc, wherein uppercase letters denote a beta-D-

USSN:10/776,934

Group Art Unit:1635

oxy-LNA and lowercase letters denote a DNA sugar, and wherein said nucleotides and/or nucleotide analogues are linked together by a phosphate group, a phosphorothioate group, or a combination thereof.

161. (New) The compound of claim 160, wherein said compound comprises the sequence $C_sT_sC_sA_sastsc_sastsgsgsC_sA_sG_sC$, wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

162. (New) The compound of claim 161, wherein said compound consists of the sequence $C_sT_sC_sA_sastsc_sastsgsgsC_sA_sG_sC$, wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

163. (New) The compound of claim 160, wherein said compound comprises the sequence $C_oT_oC_oA_oastsc_sastsgsgsC_oA_oG_oC$, wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphate linkage.

164. (New) The compound of claim 163, wherein said compound consists of the sequence $C_oT_oC_oA_oastsc_sastsgsgsC_oA_oG_oC$, wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphate linkage.

165. (New) The compound of claim 160, wherein said compound comprises the sequence $C_sT_sC_sA_sastsc_sastsgsgsC_sA_sG_sc$, wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

166. (New) The compound of claim 165, wherein said compound consists of the sequence

USSN:10/776,934

Group Art Unit:1635

C₅T₅C₅A₅s₅t₅c₅s₅a₅t₅g₅g₅C₅A₅G₅c, wherein uppercase letters denote a beta-D-oxy-INA and lowercase letters denote a DNA sugar, and wherein the subscript "5" denotes a phosphorothioate linkage.

167. (New) The compound of claim 153, wherein said compound comprises the sequence c₅t₅c₅a₅s₅a₅t₅c₅s₅a₅t₅g₅g₅c₅a₅g₅c, wherein lowercase letters denote a DNA sugar, and wherein the subscript "5" denotes a phosphorothioate linkage.

168. (New) The compound of claim 167, wherein said compound consists of the sequence c₅t₅c₅a₅s₅a₅t₅c₅s₅a₅t₅g₅g₅c₅a₅g₅c, wherein lowercase letters denote a DNA sugar, and wherein the subscript "5" denotes a phosphorothioate linkage.

169. (New) The compound of any one of claims 160-168, wherein the cytosine (C) is 5' methyl cytosine (5'-MeC).